Sensei Biotherapeutics to Present Clinical Data at Upcoming Oncology Medical Conferences

GAITHERSBURG, Md.--(BUSINESS WIRE)-- Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company discovering and developing precision immuno-oncology therapies, today announced that it will present clinical data for SNS-301, its first-in-class cancer immunotherapy candidate, at two upcoming oncology medical meetings.

The company will present results from its Phase 1 study of SNS-301 in antigen-positive patients targeting human aspartate β-hydroxylase (ASPH), a novel tumor-specific embryonic antigen, at a Poster Discussion session at the European Society for Medical Oncology (ESMO) 2018 Congress, taking place October 19-23 in Munich. Sensei will also present additional data on the antigen-specific immune responses achieved using SNS-301 in this clinical study, at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place November 9-11 in Washington DC.

Details of the presentations on SNS-301 are as follows:

European Society for Medical Oncology (ESMO) 2018 Congress



    Final Results from a Phase 1 Clinical Trial Evaluating the Safety, Immunogenicity, and Anti-Tumor Activity of SNS-301 in Men with Biochemically Relapsed Pro state Cancer

Session Type:

    Poster Discussion session – Development therapeutics / investigational immunotherapy  

Date & Time:

    October 20, 2018, 3:00 - 4:15 p.m. CET  


    Hall B3 – Room 22  

Presentation #:


Poster Display:

    In designated Poster Discussion area, displayed for the duration of the Congress  

Society for Immunotherapy of Cancer (SITC) Annual Meeting



    Characterization of antigen specific immune responses from a first-in-human study evaluating the anti-ASPH cancer vaccine SNS-301 in biochemically relapsed prostate cancer patients

Session Type:

    Poster session  

Date & Time:

    Friday, November 9, 2018, from 8 a.m. – 8 p.m. ET  
              Saturday, November 10, 2018, from 8 a.m. – 8:30 p.m. ET  


    Hall E  

Poster #:


About SNS-301

SNS-301 is a first-in-class cancer immunotherapy targeting human aspartate β-hydroxylase (ASPH), a cell surface enzyme that is normally expressed during fetal development. Following fetal development, the protein is no longer expressed. Expression of ASPH is uniquely upregulated in more than 20 different types of cancer and is related to cancer cell growth, cell motility and invasiveness. ASPH expression levels in various tumors are inversely correlated with disease prognosis. Through enhanced antigen presentation and other engineered immunotherapeutic features, SNS-301 is designed to overcome self-tolerance and induce robust and durable ASPH-specific humoral and cellular immune responses that are specific to ASPH. SNS-301 is paired with a companion diagnostic to select antigen-positive patients and is delivered through intradermal injection to facilitate administration and aid in generating robust immune response.

About Sensei Biotherapeutics

Sensei Biotherapeutics is a clinical-stage biopharmaceutical company discovering and developing precision immuno-oncology therapies to transform the cancer treatment landscape. The company is using its proprietary drug discovery platform, called SPIRIT, to discover and develop both vaccines and T-cell therapies, including SNS-301, its clinical stage cancer vaccine for the treatment of head and neck cancer and myelodysplastic syndrome, as well as other solid tumors and hematological cancers. SNS-301 targets a novel embryonic antigen and has successfully completed a Phase 1 clinical study. Sensei’s precision medicine approach in immuno-oncology includes the use companion diagnostics to select patients who are most likely to respond to its tumor-specific antigen therapies. Sensei Biotherapeutics is located in Gaithersburg, MD. For more information, please visit



The Yates Network
Kathryn Morris, 914-204-6412


Source: Sensei Biotherapeutics, Inc.

Back to news